|Mr. Glyn O. Edwards MBE||Chief Exec. Officer and Exec. Director||N/A||N/A||61|
|Mr. Erik Ostrowski||Chief Financial Officer||1.13M||N/A||44|
|Prof. Kay Davies FRS CBE||Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor||N/A||N/A||67|
|Prof. David Roblin BSc, MBBS, FRCP, MFPM||Chief Operating Officer, Chief Medical Officer and Pres of R&D||N/A||N/A||50|
|Ms. Michelle Avery||Director of Investor Relations||N/A||N/A||N/A|
Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial in patients with DMD; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials for the treatment of CDI disease. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.
Summit Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.